RPRX Royalty Pharma plc

Price (delayed)

$42.1

Market cap

$25.56B

P/E Ratio

29.24

Dividend/share

$0.72

EPS

$1.44

Enterprise value

$30.87B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The company's quick ratio has surged by 133% YoY and by 31% QoQ
The revenue has increased by 3.8% YoY
The net income has contracted by 38% YoY and by 2.8% from the previous quarter
The P/E is 33% higher than the last 4 quarters average of 22.2

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
607.18M
Market cap
$25.56B
Enterprise value
$30.87B
Valuations
Price to earnings (P/E)
29.24
Price to book (P/B)
2.52
Price to sales (P/S)
8.02
EV/EBIT
39.67
EV/EBITDA
39.67
EV/Sales
13.55
Earnings
Revenue
$2.28B
EBIT
$778.16M
EBITDA
$778.16M
Free cash flow
$1.93B
Per share
EPS
$1.44
Free cash flow per share
$4.45
Book value per share
$16.7
Revenue per share
$5.25
TBVPS
$40.05
Balance sheet
Total assets
$17.38B
Total liabilities
$7.24B
Debt
$7.1B
Equity
$10.14B
Working capital
$2.85B
Liquidity
Debt to equity
0.7
Current ratio
21.95
Quick ratio
21.91
Net debt/EBITDA
6.82
Margins
EBITDA margin
34.2%
Gross margin
100%
Net margin
26.4%
Operating margin
62.4%
Efficiency
Return on assets
3.5%
Return on equity
5.9%
Return on invested capital
3.5%
Return on capital employed
4.5%
Return on sales
34.2%
Dividend
Dividend yield
1.71%
DPS
$0.72
Payout ratio
50%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-1.08%
1 week
5.67%
1 month
2.01%
1 year
2.36%
YTD
5.65%
QTD
8.06%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.28B
Gross profit
$2.28B
Operating income
$1.42B
Net income
$602.37M
Gross margin
100%
Net margin
26.4%
Royalty Pharma's net margin has decreased by 40% YoY and by 2.6% QoQ
The net income has contracted by 38% YoY and by 2.8% from the previous quarter
The operating margin has declined by 6% year-on-year
The revenue has increased by 3.8% YoY

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
29.24
P/B
2.52
P/S
8.02
EV/EBIT
39.67
EV/EBITDA
39.67
EV/Sales
13.55
The P/E is 33% higher than the last 4 quarters average of 22.2
Royalty Pharma's EPS has decreased by 4% YoY and by 3.4% QoQ
RPRX's P/B is 11% above its last 4 quarters average of 2.3
RPRX's equity is up by 3.1% year-on-year
The P/S is 13% above the last 4 quarters average of 7.2
The revenue has increased by 3.8% YoY

Efficiency

How efficient is Royalty Pharma business performance
RPRX's ROE has plunged by 57% YoY and by 3.3% from the previous quarter
The ROA has decreased by 43% YoY and by 5% from the previous quarter
The ROIC is down by 38% YoY and by 2.8% QoQ
Royalty Pharma's return on sales has decreased by 33% YoY

Dividends

What is RPRX's dividend history
DPS
$0.72
Dividend yield
1.71%
Payout ratio
50%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 140% more than its total liabilities
The current ratio has surged by 133% year-on-year and by 31% since the previous quarter
The company's quick ratio has surged by 133% YoY and by 31% QoQ
Royalty Pharma's debt is 30% lower than its equity
Royalty Pharma's debt has increased by 22% YoY
The debt to equity has increased by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.